Imint has experienced an interesting Q2 with strong sales growth, two new agreements and continued growth of their organization. Imint has since then announced an additional license agreement with a Chinese manufacturer. We believe that Imint is well-positioned to experience future growth and reiterate our fair value of SEK 71 per share in base case.
Read the Research Update by Dennis Berggren at: https://goo.gl/if65Cn
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye – Research Powered Investment Banking. https://www.redeye.se/
